[26PO1-am2] Formulation testing-1/Dispensing, prescription audit and ordering/Drug information-1/Pharmacotherapies (Clinical)-1/(Basics)-1/Risk management/Others

[26PO1-am2-14] The risk factors associated with immune checkpoint inhibitor–related pneumonitis

○Mizuho Asada^1,2, Takahisa Mikami³, Takahiro Niimura⁴, Zamami Yoshito^5,6, Chuma Masayuyki⁷, Goda Mitsuhiro^4,5, Keisuke Ishizawa^4,5, Yoshihiro Uesawa¹ (1. Department of Medical Molecular Informatics, Meiji Pharmaceutical University, 2. Department of Pharmacy, Tokyo Medical and Dental University Hospital, 3. Department of Neurology, Tufts Medical Center, 4. Department of Pharmacy, Tokushima University Hospital, 5. Tokushima University Graduate School of Biomedical Sciences, 6. Department of Pharmacy, Okayama University Hospital, 7. Department of Hospital Pharmacy and Pharmacology, Asahikawa Medical University)